TD Cowen Cuts Danaher (NYSE:DHR) Price Target to $240.00

Danaher (NYSE:DHR) had its target price lowered by TD Cowen from $245.00 to $240.00 in a research note published on Wednesday morning,MarketScreener reports. The brokerage currently has a buy rating on the conglomerate’s stock.

Several other brokerages also recently commented on DHR. Leerink Partners increased their price objective on Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a research note on Friday, January 16th. Evercore lowered their price objective on Danaher from $254.00 to $225.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Guggenheim lowered their price objective on Danaher from $275.00 to $235.00 and set a “buy” rating for the company in a research note on Wednesday. The Goldman Sachs Group lowered their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a research note on Monday, April 13th. Finally, Wolfe Research reduced their target price on Danaher from $260.00 to $230.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. Seventeen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $242.45.

Danaher Stock Performance

Shares of Danaher stock opened at $177.31 on Wednesday. The company has a market cap of $125.49 billion, a PE ratio of 34.30, a price-to-earnings-growth ratio of 2.42 and a beta of 0.95. Danaher has a 52 week low of $175.00 and a 52 week high of $242.80. The business has a 50 day moving average price of $195.75 and a 200-day moving average price of $213.86. The company has a quick ratio of 1.51, a current ratio of 1.87 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, April 21st. The conglomerate reported $2.06 EPS for the quarter, topping the consensus estimate of $1.94 by $0.12. The firm had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The company’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.88 earnings per share. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. Equities analysts anticipate that Danaher will post 8.43 earnings per share for the current fiscal year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 24th. Shareholders of record on Friday, March 27th were issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.9%. This is a positive change from Danaher’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend was Friday, March 27th. Danaher’s dividend payout ratio is currently 30.95%.

Insiders Place Their Bets

In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total transaction of $274,573.20. Following the completion of the transaction, the executive vice president directly owned 5,099 shares of the company’s stock, valued at approximately $1,060,642.99. This represents a 20.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Danaher

Institutional investors and hedge funds have recently bought and sold shares of the company. JPL Wealth Management LLC bought a new position in Danaher during the third quarter valued at $25,000. Elevated Capital Advisors LLC bought a new position in Danaher during the fourth quarter valued at $26,000. WFA of San Diego LLC bought a new position in Danaher during the second quarter valued at $26,000. ANTIPODES PARTNERS Ltd bought a new position in Danaher during the third quarter valued at $27,000. Finally, Hilton Head Capital Partners LLC bought a new position in Danaher during the fourth quarter valued at $27,000. 79.05% of the stock is owned by institutional investors.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Guggenheim reiterated a Buy rating on Danaher, supporting demand-side interest from institutional buyers. Guggenheim Reaffirms Buy
• Positive Sentiment: An analyst price-target lift to $232 signals buy-side upside vs. current levels, which can support the stock if investors focus on medium-term earnings guidance. Price Target Raised to $232
• Neutral Sentiment: Danaher priced ~€3.0 billion of euro-denominated senior notes across maturities (2028–2038). This raises liquidity for operations or M&A but increases long-term debt on the balance sheet. Senior Notes Offering
• Neutral Sentiment: Coverage pieces question whether the recent share weakness makes DHR an attractive value play — useful for long-term investors but not an immediate catalyst. Valuation Article
• Negative Sentiment: Danaher agreed to settle shareholder litigation tied to its post‑pandemic outlook for about $172.5M, a direct hit to cash and a reminder of past forecasting issues; that likely pressured sentiment. Settlement Report
• Negative Sentiment: Short interest rose ~17.8% to 8.18M shares as of April 15 (≈1.3% of float; short-interest ratio ~2.5 days), indicating increased speculative/hedged bearish positioning that can amplify downward moves.
• Negative Sentiment: Morgan Stanley trimmed its price target (from $270 to $255), and UBS issued a pessimistic forecast—both moves add analyst-driven downside pressure despite differing target levels. Morgan Stanley PT Cut UBS Forecast
• Negative Sentiment: Analysts/commentary flag Danaher’s Masimo acquisition as adding long-term potential but creating near-term margin and integration pressure, a nearer-term risk to earnings momentum. Masimo Deal Commentary

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.